By David Siegel ( August 7, 2014, 3:11 PM EDT) -- A New Jersey federal judge on Wednesday gave the red light to Roxane Laboratories Inc.'s bid to block subsidiaries of Hetero Drugs Ltd. from manufacturing and marketing calcium acetate, a generic version of the kidney medication PhosLo, finding the subsidiaries' version of the drug likely doesn't infringe on Roxane's patent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.